Choosing the right thawing approach for your product can be quite difficult, as product volume, primary container, manufacturing stage and required level of process control all play a role. This guide helps you determine which controlled technology best fits your application.
So, which thawing approach fits your process? Start with these four questions.
1. What thawing method is best for my biopharmaceutical product?
For high-value biopharmaceuticals, controlled thawing with dedicated equipment provides defined and repeatable process conditions. Programmable profiles help keep the product within established temperature limits and reduce dependence on ambient conditions, operator timing, and subjective endpoint decisions. Controlled thawing can use conduction-based plate freeze-thaw technology or convection-based blast freeze-thaw technology.
Temperature deviations are not the only concern. Frozen single-use bags can become brittle and more vulnerable to impact, bending and point loads. Every manual transfer, repositioning step or endpoint check adds another handling event. Protective secondary packaging and a defined handling workflow can therefore be as important as temperature control.
Water baths or ambient passive thawing are further thawing methods. These are most reasonable when:
- no scale-up is planned,
- schedules are not that critical,
- and the risk of product loss are low
Water baths are typically used for small container volumes up to 5 L and add cleaning, water-quality and contamination control requirements, while ambient thawing offers less control over heat transfer, endpoint and cycle time and is typically used for larger bioprocess containers. These uncontrolled methods should still be supported by product-specific stability data and a defined thaw endpoint. For valuable products, tighter schedules or processes intended to scale, controlled thawing provides a stronger basis for reproducibility, product protection and process transfer.
Although budget constraints often prevent laboratories or small-scale manufacturers from choosing controlled thawing equipment, budget alone should not define a thawing method. No matter whether the process uses a water bath, ambient conditions or dedicated equipment, it should be reproducible, monitored and supported by product-specific data.
Freeze-Thaw recommendations by FDA
A FDA draft guidance recommends, when applicable, freeze-thaw and thermal-cycling studies during drug development to demonstrate that drug quality and container closure integrity are maintained - and will be during scale-up [[1]]. The guidance reinforces that freeze-thaw conditions should be considered already during development rather than only when commercial equipment is selected.
2. What type of container do I need to thaw?
The primary container is one of the first things to consider. Its geometry affects heat transfer, handling and equipment compatibility. It is also worth looking ahead: will the selected container and thawing method still work when the process moves from development into clinical, pilot or commercial manufacturing?
2D single-use bags: plate-based thawing
For 2D single-use bags, plate-based systems bring the protected bag into direct contact with temperature-controlled plates. This supports standardized, recipe-driven thawing under defined temperature conditions.
Single Use Support's RoSS® PFTU combines plate-based freezing and thawing with RoSS® Shell, a protective secondary packaging compatible with 2D single-use bags from different vendors. The platform is designed for automated freeze-thaw processes, from development to commercial manufacturing, with configurations for batch volumes up to 500 L and can help manufacturers and CDMOs reduce hidden costs of ambient thawing, as outlined in this case study.
[[download-1-email-detailed]]
Bottles, carboys and bulky containers: controlled air-based thawing
Freezing and thawing rigid or bulky containers is generally better suited to forced air convection than direct plate contact.
RoSS® BLST accomodates bottles, carboys, bags and other formats through a flexible internal rack system. The rigid geometry of bottles makes plate-based systems unsuitable, while controlled air can circulate around the containers. Bottle RoSS® is the equivalent of the RoSS® Shell for bottles, ensuring container closure integrity throughout cold chain management.
Integrated shaking adds another level of process control during thawing. It promotes product and temperature homogeneity, reducing the need for post-thaw mixing while helping to avoid warmer boundary layers near the container wall. Agitation can also support faster, more uniform thawing. This integrated shaking capability is a key advantage of RoSS® BLST for controlled thawing. Depending on the container arrangement, batch capacities of up to 300 L are possible.
Vials may suit either technology with qualified holders and loading patterns and thawing recipes.
3. How do batch volume and manufacturing stage impact my thawing process?
The right solution depends on more than total volume. Consider the number and size of containers, loading pattern, required turnaround time and whether capacity will increase through scale-up, scale-out or both.
Process development and R&D may prioritize flexible profiles and process transferability, while clinical and pilot-scale manufacturing require greater repeatability and documentation. GMP commercial manufacturing typically places greater emphasis on qualified recipes, capacity, electronic records, and predictable cycle planning.
RoSS® PFTU configurations support batch volumes up to 500 L, while RoSS® BLST supports up to 300 L, depending on container format and loading. Larger requirements may call for multiple units or staggered cycles. Defining the future manufacturing strategy during development helps avoid establishing a thawing process that is difficult to reproduce at larger scales.
4. How can I control temperature deviations, protect containers and meet GMP requirements?
A robust thawing process needs uniform heat transfer, defined temperature limits and a clear endpoint. Recipe-based profiles and temperature monitoring can reduce unwanted exposure and improve batch-to-batch consistency.
Thawing equipment selection should also reflect the wider workflow, from frozen storage and internal transport to loading, post-thaw hold and transfer into the next process step. Consider space, utilities, cleaning and capacity per cycle.
From clinical to GMP manufacturing, relevant criteria include:
- recipe-based operation
- electronic records and traceability
- user management
- cGMP documentation and qualification support
IQ/OQ support and a defined process performance qualification strategy help demonstrate that the equipment and process perform as intended. Integration with the site's automation and data environment may become increasingly important towards commercial scale.
Which controlled thawing equipment fits your application?
The choice ultimately comes down to the requirements of the individual process. The decision should consider product stability, primary container, batch volume and container count, required movement, temperature limits, product protection, manufacturing stage, facility constraints, documentation needs and future scale-up or scale-out.
Choose controlled thawing with Single Use Support's equipment:
- RoSS® PFTU for controlled plate-based freezing and thawing of 2D single-use bags, including protective secondary packaging.
- RoSS® BLST provides controlled air-based thawing for bags, bottles and other formats, with optional shaking when standardized movement is required.
Because these criteria can influence one another, equipment selection should be based on the complete process rather than a simple container or volume rule. Discuss your product, container configuration, batch requirements and facility constraints with the Single Use Support experts to identify and qualify the controlled thawing approach that best fits your process.
[[featured-products:Our featured products]]
References
[[1]] Food and Drug Association: Container Closure Systems for Human Drugs and Biological Products; Guidance for Industry - Draft Guidance. 2026. Regulations.gov
